Assenagon Asset Management S.A. Sells 2,061,395 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Assenagon Asset Management S.A. lowered its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 51.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,915,729 shares of the company's stock after selling 2,061,395 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.45% of Organogenesis worth $5,479,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC lifted its holdings in Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company's stock worth $8,521,000 after buying an additional 471,741 shares during the period. GSA Capital Partners LLP lifted its stake in shares of Organogenesis by 102.8% in the 1st quarter. GSA Capital Partners LLP now owns 531,218 shares of the company's stock valued at $1,509,000 after purchasing an additional 269,315 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Organogenesis in the 1st quarter valued at approximately $100,000. AQR Capital Management LLC lifted its stake in shares of Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company's stock valued at $6,353,000 after purchasing an additional 986,132 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company's stock valued at $5,702,000 after purchasing an additional 333,123 shares during the period. Hedge funds and other institutional investors own 49.57% of the company's stock.

Organogenesis Stock Down 1.3 %

Shares of ORGO traded down $0.04 on Wednesday, reaching $2.94. The stock had a trading volume of 41,395 shares, compared to its average volume of 831,944. The firm has a market capitalization of $389.76 million, a price-to-earnings ratio of 74.50 and a beta of 1.60. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.42 and a current ratio of 2.73. The company has a 50-day simple moving average of $2.88 and a 200-day simple moving average of $2.77. Organogenesis Holdings Inc. has a 12-month low of $1.96 and a 12-month high of $4.70.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.11). The firm had revenue of $130.23 million during the quarter, compared to analysts' expectations of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. Sell-side analysts predict that Organogenesis Holdings Inc. will post -0.17 EPS for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.